EGFR and neoplasm: The authors revealed ATM mutations and low E‐cadherin expression as novel supportive predictive markers.8 Adua et al analyzed primary tumor and liver metastasis samples from 7 KRAS wild‐type patients and compared the genotypes of 22 genes associated with anti‐EGFR before and after chemotherapy.